nature research

Corresponding author(s):	Michael Roberts
Last updated by author(s):	Aug 10, 2023

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

C .			
Sta	4† I	ıstı	CS

n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>

Data collection

Three of the datasets (MIMIC, Breast Cancer and NHSX COVID-19) were collected by other institutes and available on reasonable request to the data access committee of the relevant originator. For the Synthetic datasets, we generated this using a Python package as detailed in the manuscript.

Data analysis

For the preprocessing of the Breast Cancer dataset, we use our implementation provided in the code prepare_breast_data.ipynb as a Jupyter notebook by using python 3.6. For the preprocessing of a random subset of MIMIC-III dataset the code MIMIC_subset_missing_folds.ipynb is used. A full description of the preprocessing steps are included in our Supplementary Materials for both Breast Cancer and MIMIC-III datasets. The NHSX COVID-19 dataset is preprocessed by code provided in the prepare_covid_data.ipynb Jupyter notebook. All the packages and software used in these analysis are open source and publicly available.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data that support the findings of this study are openly available for the simulated, MIMIC-III and Breast Cancer datasets in our GitLab repository (10.5281/zenodo.8234032). The NHSX COVID-19 dataset is available from the originators upon completion of an approved request (see https://nhsx.github.io/covid-chest-

imaging-database/dat	ta-access). All code required to pre	e-process the data is shared in our repository.		
	t is available after completion of a ww.cbioportal.org/study/summar	training course at https://physionet.org/content/mimic3-carevue/1.4/. The Breast Cancer dataset is freely y?id=breast_msk_2018.		
Field-spe	cific reporting			
Please select the on	ne below that is the best fit for	your research. If you are not sure, read the appropriate sections before making your selection.		
X Life sciences	Behavioural & so	cial sciences Ecological, evolutionary & environmental sciences		
For a reference copy of th	ne document with all sections, see <u>natu</u>	ure.com/documents/nr-reporting-summary-flat.pdf		
Life scien	ces study des	ign		
All studies must disc	close on these points even whe	en the disclosure is negative.		
Sample size	Inherent to the data collected from the different sources for the clinical datasets. For the Synthetic (N) data, a sample size of 1000 was chosen, as with 25 features an event per variable of 40 gives a low risk of bias in the data and for a predictive model based on the PROBAST guidelines. The Synthetic (N,C) dataset has 100 samples with 20 informative features and 5 useless features again with a low risk of bias per PROBAST.			
Data exclusions	For the clinical datasets NHSX COVID-19 and Breast Cancer, features were removed that were >50% incomplete and samples were removed that were >50% incomplete to ensure there was sufficient data to perform reasonable imputation. The Synthetic dataset is complete by design. For the MIMIC-III dataset, all incomplete records are excluded from the beginning as the data is of sufficient scale.			
Replication	We have been careful to ensure t	that the data processing, imputation, classifiers and analysis are completely reproducible.		
Randomization	N/A			
Blinding	N/A			
We require informatio system or method liste	on from authors about some types	materials, systems and methods of materials, experimental systems and methods used in many studies. Here, indicate whether each material, are not sure if a list item applies to your research, read the appropriate section before selecting a response. Methods		
n/a Involved in the	<u> </u>	n/a Involved in the study		
Antibodies	·	ChIP-seq		
Eukaryotic o		Flow cytometry		
_	— —			
	d other organisms earch participants			
Dual use res	search of concern			
Clinical data				
	about <u>clinical studies</u> I comply with the ICMJE <u>guidelines</u>	s for publication of clinical research and a completed <u>CONSORT checklist</u> must be included with all submissions.		
Clinical trial regist	ration N/A			
Study protocol	N/A			
Data collection	We use existing clinical datasets, which are referenced in the manuscript and data collection methodology has been detailed at source.			

The outcomes are inherent to the datasets. Mortality is the outcome of interest for all clinical datasets.

Outcomes